The number of FDA-approved monoclonal antibodies (mAbs) continues to grow, while those in late-stage development rose more than 30% between 2021 and 2022. Given the relative value of being first to market, biopharmaceutical companies are looking to shrink the 10 or more years it usually takes for a biologic candidate to progress from drug discovery to regulatory approval.
Increase speed, reduce risk and maintain quality of mAbs by partnering with a CDMO that has a comprehensive program for moving from discovery to clinical batches of a new biologic.
- Rapid antibody discovery process
- Cell line development using CHO-GSN℠ platform
- Cell bank generation and characterization with Solentim® VIPS™
- Upstream process development using Sartorius® Ambr® 15 Cell Culture Bioreactor System for optimized culture conditions
- Downstream process development
- Drug product formulation development and manufacturing
- Identifying critical quality attributes (CQAs)
- Quality systems at Curia
- Specializing in First-to-Human manufacturing support
Ready to move from idea to impact?
Whether you have a question for our team or an opportunity you’re eager to pursue, one of our experts can help you get started.
Contact Us